Pioneering the Future of Plant-Based Psychedelic Medicine

Strategic investment opportunity in mescaline-assisted therapy at the forefront of Oregon's psychedelic renaissance

Explore Investment Opportunities

About Innergreen Visions

Innergreen Visions presents a unique investment opportunity in the rapidly expanding psychedelic medicine market. Based in Portland, Oregon, we operate the first large-scale San Pedro conservation project in the U.S., with a climate-controlled indoor facility housing over 2,000 cacti specimens.

Our strategic position as a trailblazer in mescaline-assisted psychotherapy targets transformative treatments addressing addiction, depression, PTSD, and other mental health conditions. With your investment, we will scale operations, accelerate research, and establish Innergreen Visions as the market leader in this emerging field.

San Pedro Cactus

Our Business Model

Innergreen Visions Laboratory

Our vertically integrated business model positions us for exceptional ROI across multiple revenue streams. We're not just cultivators—we're building a comprehensive ecosystem spanning cultivation, research, and therapeutic applications with three distinct phases of growth:

  • Phase 1: Expand research capabilities and alkaloid profiling to develop proprietary compounds
  • Phase 2: Establish licensed service center and manufacturing facilities
  • Phase 3: Scale therapeutic protocols under future Oregon Mescaline Services regulations

Our strategic location in Portland, Oregon—a progressive hub for psychedelic medicine policy—provides first-mover advantage in this emerging market.

Market Opportunity & Growth Potential

The psychedelic medicine market is projected to reach $10.75 billion by 2027, with Oregon leading regulatory innovation. Following the successful passage of Measure 109 (Oregon Psilocybin Services Act), we anticipate similar frameworks for mescaline therapy—creating a limited early-investment opportunity.

Our strategic vision includes establishing Oregon Mescaline Services as a parallel regulatory framework, positioning Innergreen Visions with a unique advantage in this untapped market. With 30+ million Americans suffering from treatment-resistant mental health conditions, the demand for alternative therapies presents substantial growth potential.

Early investors will benefit from our established infrastructure, proprietary research, and strategic positioning as we scale to meet the projected 20-30% annual growth in the psychedelic medicine sector over the next decade.

Psychedelic Therapy

Research & Innovation

Proprietary Alkaloid Profiles

Our exclusive collection contains valuable compounds beyond mescaline, including 3,4-DMPEA, hordenine, and 3-Methoxytyramine (3-MT)—creating multiple patentable opportunities and therapeutic applications with significant IP value.

Advanced Analytical Methods

Our cutting-edge gas chromatography-mass spectrometry (GC-MS) analysis creates a competitive advantage through precise alkaloid profiling across our 2,000-specimen collection—establishing valuable datasets unavailable to competitors.

Patentable Biosynthetic Compounds

We're developing proprietary biosynthetic analogues with enhanced efficacy and safety profiles—creating a pipeline of novel compounds with significant commercial potential and strong intellectual property protection.

Investment Opportunity

Investment Opportunity

Innergreen Visions offers qualified investors a ground-floor opportunity in the rapidly expanding psychedelic medicine market. As the first large-scale San Pedro conservation project in the U.S., we provide early access to proprietary compounds, patentable IP, and first-mover advantage in an emerging therapeutic category.

Capital Allocation Strategy:

  • Research & Development (40%): Expand alkaloid profiling capabilities, GC-MS analysis infrastructure, and biosynthetic analogue development pipeline
  • Regulatory & Licensing (25%): Position Innergreen Visions as a licensed service center, manufacturer, and laboratory under emerging frameworks
  • Operations & Talent (20%): Secure key scientific personnel and expand our climate-controlled cultivation facility
  • IP Development (10%): Patent filing and protection for novel compounds and therapeutic protocols
  • Strategic Reserves (5%): Capital reserve for opportunistic expansion and regulatory adaptation

Projected ROI: 5-7x return within 36-48 months through strategic partnerships, licensing agreements, and potential acquisition opportunities as the psychedelic medicine market matures.

Secure Your Position in the Psychedelic Renaissance

Limited investment opportunities available for qualified investors. Join us in transforming mental healthcare while generating exceptional returns.

Schedule Investor Call